| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,2 k € | -55.6% | 25,2 k € | 0.0% | 25,2 k € | +19.1% | 21,2 k € | -15.4% | 25,0 k € | -33.3% | 37,5 k € | +0.6% | 37,3 k € | +2.4% | 36,4 k € | -9.2% | 40,1 k € | +3.9% | 38,6 k € | 0.0% | 38,6 k € | |
| Gross margin | 3,1 k € | -80.5% | 15,8 k € | +36.5% | 11,6 k € | -18.8% | 14,3 k € | -22.1% | 18,3 k € | -34.0% | 27,8 k € | -12.8% | 31,8 k € | -4.8% | 33,5 k € | -1.8% | 34,1 k € | -7.7% | 36,9 k € | +0.2% | 36,8 k € | |
| EBITDA | 2,7 k € | -82.5% | 15,4 k € | +37.3% | 11,2 k € | -19.3% | 13,9 k € | -20.1% | 17,4 k € | -36.5% | 27,4 k € | -12.9% | 31,5 k € | -4.9% | 33,1 k € | -1.8% | 33,7 k € | -7.8% | 36,6 k € | +0.2% | 36,5 k € | |
| Operating profit | 2,7 k € | +120.8% | -13,0 k € | +24.5% | -17,1 k € | -18.6% | -14,5 k € | -31.9% | -11,0 k € | -1042.4% | -960,0 € | -134.4% | 2,8 k € | -36.5% | 4,4 k € | -12.2% | 5,0 k € | -36.1% | 7,9 k € | +1.1% | 7,8 k € | |
| Profit/loss | 2,7 k € | +120.6% | -13,0 k € | +31.7% | -19,0 k € | -25.2% | -15,2 k € | -7.8% | -14,1 k € | -377.8% | -2,9 k € | -477.8% | -510,0 € | -171.2% | 716,0 € | +17.4% | 610,0 € | -74.9% | 2,4 k € | +848.8% | 256,0 € | |
| Equity | -51,8 k € | +4.9% | -54,5 k € | -31.3% | -41,5 k € | -84.5% | -22,5 k € | -207.3% | -7,3 k € | -208.3% | 6,8 k € | -30.4% | 9,7 k € | -5.0% | 10,2 k € | +7.6% | 9,5 k € | +6.9% | 8,9 k € | +37.6% | 6,5 k € | |
| Total assets | 126,4 k € | -5.4% | 133,6 k € | -13.3% | 154,1 k € | -10.7% | 172,6 k € | -11.6% | 195,1 k € | -12.8% | 223,9 k € | +52.5% | 146,8 k € | -14.9% | 172,5 k € | -15.0% | 202,8 k € | -39.6% | 335,8 k € | -8.6% | 367,5 k € | |
| Cash | 243,0 € | +1925.0% | 12,0 € | -87.5% | 96,0 € | +14.3% | 84,0 € | +600.0% | 12,0 € | -81.3% | 64,0 € | -73.6% | 242,0 € | -86.0% | 1,7 k € | +209.8% | 559,0 € | +69.4% | 330,0 € | -0.3% | 331,0 € | |
| Debts | 178,2 k € | -5.2% | 188,0 k € | -3.9% | 195,6 k € | +0.3% | 195,1 k € | -3.6% | 202,5 k € | -6.7% | 217,1 k € | +58.3% | 137,1 k € | -15.5% | 162,3 k € | -16.1% | 193,3 k € | -40.9% | 326,9 k € | -9.5% | 361,0 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Lubbeek · incorporated on 22/01/2014
Private company with limited liability with a balanced profile. Cash position rising (+1925.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Beisol Pharma Tienen is a Private company with limited liability incorporated in 2014. Its main activity is: Leasing of intellectual property and similar products, except copyrighted works. Its registered office is in Lubbeek.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.